Exercise in People With Cystic Fibrosis on CFTR Modulator Therapy

Last updated: March 13, 2024
Sponsor: Universidad Politecnica de Madrid
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cystic Fibrosis

Lung Disease

Scar Tissue

Treatment

Exercise

Clinical Study ID

NCT06322446
PI23/00299
  • Ages 6-20
  • All Genders

Study Summary

Recently, the treatment of Cystic Fibrosis (CF) incorporated new modulators/enhancers of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). It is thus increasingly important to study the side effects of these drugs, their extrapulmonary effects and possible interaction with other drugs and with exercise. For this purpose, a randomized controlled trial is proposed to determine the effects of a telematic exercise intervention on muscle health, in a group of 48 children and adolescents with CF treated with these new generation CFTR modulators. They will be randomly assigned to two groups (exercise and control group). The effect of the intervention will be analysed measuring the variables of muscle health, cardiorespiratory fitness, lung function, body composition, inflammatory biomarkers and miRNAs. After completion of the intervention program, adherence to exercise and clinical evolution after one year will be analysed.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • patients diagnosed with CF.
  • patients between 6-20 years of age.
  • patients receiving treatment with new CFTR protein modulating medication
  • reading, acceptance and signing of the informed consent form.

Exclusion

Exclusion Criteria:

  • CF patients with symptoms of pulmonary exacerbation during the last four weeks.
  • with a diagnosis of other cardiorespiratory lung diseases progressing to a symptom ofpersistent respiratory dysfunction.
  • CF patients with musculoskeletal alterations that influence assessments.
  • CF patient who is pregnant during the time of the study
  • CF patient with cognitive impairment;
  • CF patient with incomplete dosing of modulator therapy;

Study Design

Total Participants: 48
Treatment Group(s): 1
Primary Treatment: Exercise
Phase:
Study Start date:
February 27, 2024
Estimated Completion Date:
December 23, 2025

Study Description

Specific objectives

  1. To determine the effects of a strength exercise intervention in a group of children and adolescents with cystic fibrosis treated with new generation CFTR modulators on: (1.i) peripheral muscle strength; (1.ii) respiratory muscle strength; (1.iii) muscle mass and (1.iv) biomarkers of muscle damage.

  2. To determine the effects of a strength exercise intervention in a group of children and adolescents with cystic fibrosis being treated with new generation CFTR modulators on: (2.i) cardiorespiratory fitness; (2.ii) body composition and (2.iii) lung function.

  3. To determine the effects of a strength-based exercise intervention in a group of children and adolescents with cystic fibrosis treated with new-generation CFTR modulators on: (3.i) biomarkers of inflammatory status and (3.ii) expression of associated miRNAs.

  4. To determine the effects of a strength-based exercise intervention in a group of children and adolescents with cystic fibrosis treated with the new generation CFTR modulators on the levels of Elexaxcaftor/Ivacaftor/Tezacaftor and their metabolites.

  5. To assess the clinical evolution and adherence to exercise after 6 months of the programme in children and adolescents with cystic fibrosis treated with the new generation of CFTR modulators.

Connect with a study center

  • Facultad de Ciencias de la Actividad Física y Deporte - INEF UPM

    Madrid, 28040
    Spain

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.